Neurodegenerative Disease Targets (α-Syn, Tau, etc.)
Neurodegenerative Diseases (e.g., Parkinson's, Alzheimer's)
Research/Pre-clinicalActive
Key Facts
Indication
Neurodegenerative Diseases (e.g., Parkinson's, Alzheimer's)
Phase
Research/Pre-clinical
Status
Active
Company
About new/era/mabs
new/era/mabs is a private, platform-based biotech service provider leveraging its proprietary selmax technology for high-throughput antibody discovery. Its core value proposition is delivering antibody leads four times faster than conventional methods by using immortal antigen-specific cell pools that allow for infinite screening. The company serves research, diagnostic, and therapeutic partners with tailored antibody sets and manufacturing, with notable applications in infectious diseases (e.g., SARS-CoV-2) and neurodegenerative targets. It appears to be in an early-revenue stage, collaborating with academic and industry partners to advance its platform.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases (e.g., Parkinson's, Alzheimer's) Drugs
| Drug | Company | Phase |
|---|---|---|
| Neurology Program(s) | Mercury Bio | Pre-clinical |